News Releases

Rahway, N.J. – Sept. 13, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced new data demonstrating the safety and efficacy of NUMELVI® (atinvicitinib) Tablets for Dogs and MOMETAMAX ULTRA® (gentamicin, posaconazole, and mometasone furoate otic suspension) for dogs. These data were presented at the 35th […]

Read more

NUMELVI, a highly-selective, second-generation JAK inhibitor for dogs, delivers at least 10-fold greater selectivity for JAK1 compared with JAK2, JAK3, and tyrosine kinase (TYK)–2, and is suitable for dogs as young as 6 months. RAHWAY, N.J., July 24, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today […]

Read more

Data show pet owners face difficulties with consistent compliance, while veterinarians worry about inconsistent or incorrect medication administration In the U.S. Two-thirds of veterinarians note that most pet owners do not follow year-round treatment plan, despite evidence that fleas and tick are present during all seasons RAHWAY, N.J., August 19, 2025 – MSD Animal Health, […]

Read more

Data to showcase depth and breadth of the BRAVECTO® (fluralaner) portfolio including the injectable and oral endectocide combination formulations Rahway, NJ, August 18, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced it will present multiple studies in support of the BRAVECTO® fluralaner portfolio at the […]

Read more

NUMELVI from MSD Animal Health is the First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Treatment of Pruritus Associated with Allergic Dermatitis Including Atopic Dermatitis and Treatment of Clinical Manifestations of Atopic Dermatitis in Dogs RAHWAY, N.J., July 24, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., […]

Read more

12-Month Parasiticide Treatment for Dogs Offers Unrivaled Duration of Flea and Tick Protection Compared to Existing Products RAHWAY, N.J., July 10, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug Administration (FDA) approval of BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) […]

Read more

Rahway, NJ., June 12, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for the NOBIVAC® L6 and NOBIVAC® LoVo L6 vaccines. If the European Commission (EC) adopts the recommendation, the […]

Read more

Parasiticide Treatment for Dogs Offers Unrivaled Duration of Flea and Tick Protection Compared to Existing Products Rahway, N.J., February 11, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that S&P Global Animal Health awarded the injectable formulation of BRAVECTO® (fluralaner) the 2024 Best New Companion […]

Read more